CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Tablet Methylprednisolone (4 or 16 mg)drug
Likely dose
Tablet Methylprednisolone (4 or 16 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00929981
NCT00929981N/ACompleted
CompareCT.gov

Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects

Pfizer·observational·Posted Jun 30, 2009·Updated Jan 2, 2019

In Brief

An observational study evaluating Tablet Methylprednisolone (4 or 16 mg) for Dermatitis, Contact. Completed, enrolled 80 participants across 4 sites.

Detailed Summary

This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability of Medrol in treating contact dermatitis in Indian patients. Patients with contact dermatitis who have been prescribed for Medrol will be enrolled into the study and will be followed up for the resolution of symptoms

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Contact
CountriesIndia
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 30, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.0 years ago

Interventions

Tablet Methylprednisolone (4 or 16 mg)drug

Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information